Trial Profile
Phase I/II pilot study of gevokizumab [XOMA 052] in resistant uveitis of Behcet's disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2011
Price :
$35
*
At a glance
- Drugs Gevokizumab (Primary)
- Indications Behcet's syndrome; Panuveitis; Posterior uveitis; Retinal vascular occlusion
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 21 Jul 2011 New trial record